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Abstract 
Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or 
prevent pathological thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the 
swelling disorder hereditary angioedema. While several protein based inhibitors with high affinity for 
activated FXII (FXIIa) were developed, the generation of small molecule inhibitors has been challenging. 
In this work, we have generated a potent and selective FXIIa inhibitor by optimizing a peptide macrocycle 
that was recently evolved by phage display (Ki = 0.84 ± 0.03 nM). A fluorine atom introduced in the para-
position of phenylalanine enhanced the binding affinity as much as 10-fold. Furthermore, we improved the 
proteolytic stability by substituting the N-terminal arginine by norarginine. The resulting inhibitor 
combines high inhibitory affinity and selectivity with a good stability in plasma (Ki = 1.63 ± 0.18 nM, 
>27,000-fold selectivity, t1/2 plasma = 16 ± 4 h). The inhibitor efficiently blocked activation of the intrinsic 
coagulation pathway in human blood ex vivo. 
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Introduction 
FXII, originally called Hageman factor, is a serine protease that plays an important role in the kallikrein-
kinin system and the intrinsic coagulation pathway.
1
 It is expressed as an 80 kDa zymogen, primarily by 
hepatocytes, and circulates in plasma at a concentration of around 0.4 µM. FXII is converted into its 
activated form, FXIIa, by proteolytic cleavage between the heavy chain and the enzymatic light chain. 
This process is initiated when blood is exposed to negatively charged surfaces or compounds. FXIIa has 
the capacity to cleave factor XI, initiating the intrinsic coagulation pathway, and plasma kallikrein, 
activating the kallikrein-kinin system.
1
 Activated plasma kallikrein can reciprocally activate FXII, leading 
to rapid activation of the contact system. FXIIa can also trigger the complement and fibrinolytic systems. 
Human and animals deficient in FXII do not show abnormal bleeding from injury sites and have a normal 
hemostatic capacity. The physiological role of FXII and its benefit for individuals are not completely 
understood but are subject of active research.
2, 3
 
 
While the beneficial function of FXII for the body is currently not fully understood, more is known about 
its harmful role. FXII activity causes or contributes to a number of medical conditions leading to 
coagulation and/or inflammation.
4
 The protease has received much attention in recent years due to its role 
in thrombosis. Mice deficient in FXII have a much reduced risk of thrombus formation and are protected 
from experimental ischemic stroke and pulmonary embolism.
5, 6
 This observation and the limited role of 
FXII in hemostasis raised the prospect that inhibiting FXIIa could offer an antithrombotic therapy with 
low bleeding risk. The role of FXII in thrombosis has been confirmed in various experimental animal 
models, including rat, rabbit and baboon.
4
 Several in vivo activators of the plasma contact system were 
reported, including platelet and bacterial polyphosphates, extracellular RNA and DNA, amyloid β peptide 
and misfolded proteins.
1
 FXII also constitutes a constant threat in medical procedures that depend on 
extracorporeal circulation such as cardiopulmonary bypass surgery, extracorporeal membrane oxygenation 
(ECMO), or hemodialysis.
7, 8
 In these procedures, contact with the materials of the medical devices, such 
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as tubing and membranes, can activate FXII and trigger the coagulation and inflammation pathways. FXII 
can also be activated by contact with catheters which can lead to catheter occlusion and thrombosis.
9
 In 
hereditary angioedema (HAE), a life-threatening inherited swelling disease, FXIIa activates plasma 
kallikrein that in turn cleaves high-molecular-weight kininogen to release the vasoactive hormone 
bradykinin.
10
 HAE type I and II result from a deficiency (type I) or malfunction (type II) of C1 esterase 
inhibitor, which is the main inhibitor of plasma kallikrein and FXII. In type III HAE, mutations in FXII 
cause recurrent edema attacks.
11
 
 
The important role of FXII in multiple diseases prompted academic laboratories and pharmaceutical 
companies to develop inhibitors of the protease.
4
 A range of natural proteins that inhibit FXIIa with high 
affinity were identified and exploited to block FXIIa in experimental animal models.
4, 12, 13
 Monoclonal 
antibodies either preventing activation of FXII or inhibiting the activated FXIIa were developed.
4
 The 
humanized antibody 3F7 inhibited arterial and venous thrombosis in mouse and rabbit, and prevented 
coagulation in extracorporeal circulation in rabbits.
7
 The antibody 15H8 blocked thrombosis in mice and 
baboon.
14
 The development of small molecule FXIIa inhibitors has been challenging. The high structural 
similarity of FXII to numerous homologous trypsin-like serine proteases makes it difficult to generate 
selective inhibitors.
15, 16
 Our laboratory has recently developed selective FXIIa inhibitors based on peptide 
macrocycles that have a relatively small size (< 2000 Da) and that are accessible to chemical synthesis.
17, 
18
 The best inhibitor reported is the bicyclic peptide 1 (FXII618; Figure 1a), inhibiting FXIIa with a Ki of 
8.1 ± 0.7 nM and has a more than 2,000-fold selectivity over physiologically relevant homologous 
proteases. The peptide macrocycle inhibited the intrinsic coagulation pathway with an EC2x for the 
activated partial thromboplastin time (aPTT) of around 3 µM, without affecting the prothrombin time (PT) 
at high concentrations (< 20% increase at 40 µM). We demonstrated that the inhibitor can be applied as a 
reagent for the inhibition of contact activation in diagnostic coagulation assays.
17
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For therapeutic application, a synthetic FXIIa inhibitor must block the protease with high affinity. In this 
work, we aimed at developing high affinity FXIIa inhibitors by improving the binding affinity of the 
above described bicyclic peptide 1. In the phage display selections that had been performed to isolate 
peptide 1, all of the bicyclic peptides that were screened contained exclusively natural amino acids. 
Herein, we proposed to synthesize and screen variants of peptide 1 containing unnatural amino acids. In 
addition, we aimed at improving the stability of peptide 1 to prevent proteolytic degradation when the 
peptide is applied in vivo. 
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Results and Discussion 
Improving the inhibitory activity 
Based on sequence similarities of peptides isolated in the phage selections against FXIIa,
17
 the four amino 
acids of the first ring (Phe3, Arg4, Leu5, Pro6) and the middle two amino acids of the second ring of 
bicyclic peptide 1 (Gln9, Leu10) appeared to be most important for the binding (Figure 1a). In a first 
attempt to improve the inhibitory activity of peptide 1, we chose to replace the amino acids in these 
positions with natural amino acids having similar side chains. Suitable amino acid substitutions were 
chosen using the two scoring matrices BLOSUM62 and PAM250 that indicate the evolutionary 
substitution probability of an amino acid by another one (Table 1). To allow precise quantification of the 
synthesized peptides by absorption spectrometry, a tryptophan residue was appended to the C-terminus of 
all peptides. Peptide 1 with a C-terminal Trp, named peptide 2, had a Ki of 10.2 ± 0.5 nM versus 8.1 ± 0.7 
nM of the original peptide and thus a comparable activity. A total of 26 bicyclic peptides, each having one 
amino acid substituted in one of the six positions, were synthesized. While none of the peptides had an 
improved Ki (Table 1), valuable structure-activity relationship (SAR) data was obtained. In the position of 
Phe3, replacement of phenylalanine with tryptophan conserved the activity (peptide 3; Ki = 12 ± 2). All 
other amino acid substitutions in this positon reduced the activity more than 2-fold (tyrosine, leucine, 
proline; peptides 4-6) or more than 10-fold (alanine, valine, isoleucine; peptides 7-9). In position Arg4, 
only the substitution to lysine was tested as this residue should have a positive charge to form an 
electrostatic interaction with Asp189 (trypsin numbering) at the bottom of the S1 binding pocket of FXIIa. 
Lysine in this position reduced the inhibitory activity 10-fold (peptide 10; Ki = 111 ± 8). In the position of 
Leu5, all substitutions, even those with amino acids closely resembling leucine such as valine (peptide 11) 
or isoleucine (peptide 12), reduced the affinity more than 50-fold. Peptides containing methionine (peptide 
13) or alanine (peptide 14) in this position did not inhibit FXIIa at the highest concentration tested (3 µM). 
In position Pro6, two of the amino acid replacements reduced the activity less than 2-fold, namely alanine 
(peptide 15) and leucine (peptide 18). In the second macrocyclic ring, all of the substitutions reduced the 
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activity of peptide 2 substantially. In positions Gln9 and Leu10, the smallest losses were seen for 
substitutions of aspartate (peptide 21, 54-fold) and isoleucine (peptide 26, 8-fold), respectively.  
 
In a second attempt to improve the activity of peptide 1, we chose to replace the amino acids with 
unnatural residues that are structurally similar to the natural ones (Table 2). In position Phe3, unnatural 
amino acids were tested resembling phenylalanine (peptides 29-32) and tryptophan (peptides 33-37), as 
peptides with these two natural amino acids were the most active (peptides 2 and 3). Two of the 
phenylalanine analogues reduced the binding affinity around 30-fold (peptides 29 and 30) and two of them 
did not inhibit FXIIa at the highest concentration tested (1 µM; peptides 31 and 32). Two out of the five 
peptides with tryptophan analogues had slightly improved activity: peptide 33 containing 2-
naphthylalanine had a 1.7-fold improved inhibitory activity (Ki = 6.0 ± 0.6) and peptide 35 containing 3-
benzothienylalanine showed a 1.5-fold improvement (Ki = 6.8 ± 1.8). In position Arg4, the amino acid was 
replaced with one lysine analogue (homolysine; peptide 38) and three arginine analogues (homoarginine, 
norarginine and 4-guanidinophenylalanine; peptides 39-41). All of these substitutions reduced the binding 
affinity of the peptide 5-fold or more. In the two positions Leu5 and Leu9, several aliphatic amino acids 
structurally resembling leucine were tested. All of the substitutions in position Leu5 greatly reduced the 
binding affinity wherein the smallest drop in affinity was found for norvaline (22-fold; peptide 42). In 
position Leu10, all the five unnatural amino acids reduced the affinity by less than 8-fold. 
 
Many of the 48 peptide variants described above had substantially reduced activities, despite the fact that 
only one amino acid was replaced at a time and that most of the inserted amino acids were structurally 
similar to the substituted ones. In a third attempt to improve the inhibitory activity of peptide 1, we aimed 
for amino acid substitutions that would result in only small structural changes in the side chains. We chose 
to modify position Phe3 as this was the only site in which two substitutions with unnatural amino acids 
had yielded slightly improved inhibitors (Table 3). The addition of a methyl group to the phenyl ring of 
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Phe3 in ortho- (peptide 51) and para-position (peptide 53) decreased the activity around 4-fold. In 
contrast, a methyl group in meta-position increased the affinity 2.7-fold (peptide 52; Ki = 3.7 ± 0.2). This 
result indicated that some space around the side chain of phenylalanine is available but that the space is 
limited. We subsequently modified the phenyl ring of Phe3 by introducing heteroatoms or by 
halogenation, both modifications that conserved the size and shape of the amino acid side chain. 
Replacement of a carbon atom with nitrogen in the phenyl ring in meta-position improved the activity 
around 3-fold (peptide 54; Ki = 3.0 ± 0.1). The same substitution in para-position reduced the inhibitory 
activity around 6-fold (peptide 55). Substitution of hydrogen atoms on the phenyl ring with halogen atoms 
altered the activity dramatically in both directions. Fluorine in ortho-position reduced the activity around 
2.5-fold (peptide 56). In contrast, fluorine in meta- and para-position enhanced the activity 2- and 11-fold, 
respectively (peptide 57: Ki = 4.5 ± 0.4; peptide 58: Ki = 0.89 ± 0.15). Bicyclic peptide 58 was the first 
synthetic FXIIa inhibitor with a subnanomolar inhibitory constant. We subsequently tested more 
electronegative atoms or groups in para-position. Iodine in this position reduced the activity 9-fold 
(peptide 59) and a nitro group improved the binding affinity 6-fold (peptide 60; Ki = 1.64 ± 0.19). Finally, 
the peptide with the best inhibitory activity, peptide 58 containing a 4-fluorophenyl substitution in position 
Phe3, was synthesized without the C-terminal tryptophan that was introduced at the beginning to enable 
precise determination of the concentration based on absorption. The resulting peptide 61 (also termed 
FXII800), differing from peptide 1 only by the fluorine atom in phenylalanine, had a Ki of 0.84 ± 0.03 nM 
and thus displayed an approximately 10-fold improvement in inhibitory activity (Table 4).  
 
Structural modeling and interactions of 4-fluoro-phenylalanine 
The large affinity improvement achieved by only replacing a hydrogen atom with fluorine in Phe3 raised 
the question about the underlying molecular basis. In protein-ligand interactions, fluorine can strengthen 
binding affinities through direct interactions with proteins (e.g. polar interactions, hydrophobic effects) or 
by influencing other groups of the ligand that interact with the protein (e.g. change of pKa and thus 
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protonation state, change of electron distribution in an aromatic ring).
19, 20
 We analyzed the environment of 
Phe3 in a structural model of the peptide 61 bound to FXIIa (Figure 1b). The structure was obtained by 
simply replacing the hydrogen atom in the para position of Phe3 with fluorine in the previously developed 
model for the complex peptide 1:FXIIa (PDB file ‘FXIIa-61_model’ in Supporting Information).
17
 The 
first macrocyclic ring of the bicyclic peptide containing the FRLP motif fits perfectly into the active site of 
FXIIa in terms of shape and polarity. The side chain of 4-fluoro-phenylalanine is buried in an aromatic 
pocket that is formed by two surface loops of FXIIa. The fluorine atom is in close proximity to positively 
polarized C=O and H-Cα groups and can potentially form polar interactions. A possible indirect effect of 
fluorine could be an alteration of the electron distribution in the aromatic ring which may enhance π-π 
stacking interactions between the 4-fluoro-phenylalanine and facing   aromatic amino acids His393 and 
Tyr439. 
 
Improving the proteolytic stability 
The stability of the FXIIa inhibitors can be assessed by incubating the bicyclic peptides in blood plasma 
and by subsequently measuring the remaining inhibitory activity in an assay with FXIIa and a fluorogenic 
substrate. Prior to this measurement, the plasma/bicyclic peptide samples were heat-inactivated to prevent 
cleavage of the fluorogenic substrate by other blood proteases or inhibition of FXIIa by blood-derived 
inhibitors. The assay quantifies not only the activity of intact bicyclic peptide but also the activity of 
potential metabolic products. Bicyclic peptide 1 was found to be inactivated by proteolysis when 
incubated in human plasma at 37 °C for extended time periods (t1/2 = 4 ± 2 h). While a half-life of four 
hours is sufficient to block contact activation in vitro in coagulation assays, as demonstrated in our 
previous work,
17
 it may not be long enough for clinical applications in which FXIIa presumably needs to 
be inhibited for longer time periods. Mass spectrometric analysis of peptide 1 incubated in human plasma 
showed that the first proteolytic modification is removal of a 156 Da fragment corresponding to the mass 
of arginine. Derivatives of bicyclic peptide 1 lacking either the N- or C-terminal arginine had Ki values of 
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330 ± 30 nM (peptide 62) and 9.3 ± 0.6 nM (peptide 63), respectively (Table 4). This result suggested that 
plasma proteases clip off the arginine at the N-terminus. To improve the stability, we searched for amino 
acid substitutions in position Arg1 that i) do not reduce significantly the binding affinity, and ii) prevent 
proteolytic cleavage of the first amino acid. Bicyclic peptides containing substitutions in position Arg1 
were synthesized without the C-terminal tryptophan residue (Table 5). Natural amino acids such as 
isoleucine, valine and alanine in place of Arg1 all reduced the affinity > 5-fold (peptides 64-66). 
Replacement with lysine conserved the binding affinity (peptide 67; 9.0 ± 0.9 nM), suggesting that a 
positive charge in the side chain is important. D-arginine reduced the binding affinity 3-fold (peptide 68; 
Ki = 34.4 ± 0.7 nM). Based on this structure-activity data, we tested a number of unnatural amino acids 
carrying positively charged side chains (peptides 69-72). These peptides had a comparable or slightly 
reduced affinity, with Ki value between 6.5 and 15 nM.  
 
Next, we tested the stability of the bicyclic peptides 69-72, using the assay described above (Table 5). 
Plasma proteases were heat-inactivated by incubating the samples at 65 °C for 20 minutes. The heat-
treatment did not affect the activity of the bicyclic peptides. Two of the four peptides had an improved 
stability compared to peptide 1 (Figure 2a). The longest half-life, 22 ± 3 h and thus a 5.5-fold improved 
stability compared to peptide 1, was found for peptide 71 which has a norarginine residue at the N-
terminus. Finally, we combined the norarginine substitution with the amino acid replacement that most 
improved the inhibitory activity of peptide 1 (4-fluoro-phenylalanine in position 3 of the peptide). The 
resulting peptide 73, also termed FXII801, had a Ki of 1.63 ± 0.18 nM and a plasma half-life of 16 ± 4 h. 
 
Target selectivity 
The target selectivity of peptide 73 was assessed by measuring the inhibition of structurally related or 
functionally important proteases and compared to the specificity profile of peptide 1 (Figure 2b).
17
 Eight 
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of the ten proteases were inhibited by less than 20% at the highest inhibitor concentration tested (40 µM). 
Only two of the paralogous proteases were inhibited more than 50% by peptide 73 at the tested 
concentrations, namely trypsin (Ki = 1.30 ± 0.01 µM) and plasma kallikrein (Ki = 45.1 ± 1.5 µM). The 
same two proteases were also inhibited by the peptides 1 and 61 at similar extents. These results showed 
that the affinity towards FXIIa could be improved while the activity towards other proteases remained 
essentially unchanged. The new FXIIa inhibitor peptide 73 exhibits a good selectivity of 800-fold over 
trypsin (a protease that is not present in the blood) and at least a 27,000-fold selectivity over all of the 
other tested plasma proteases. 
 
Inhibition of the intrinsic coagulation pathway 
The ability to selectively suppress the intrinsic coagulation pathway was assessed in in vitro coagulation 
assays. aPTT and PT measure the time to coagulation upon initiation of the intrinsic and extrinsic 
coagulation pathway, respectively. Coagulation via the intrinsic pathway was triggered by addition of 
silicon dioxide particles, plant phospholipids and calcium. Coagulation via the extrinsic pathway was 
triggered with recombinant human tissue factor, synthetic phospholipids and calcium. The tests were 
performed in human plasma in the presence of different concentrations of FXIIa inhibitor. Selective FXIIa 
inhibition is expected to increase aPTT but not PT. The coagulation tests were carried out using peptide 
61, the most potent inhibitor, peptide 73, the most stable variant, and the previously developed FXIIa-
inhibitor peptide 1, for comparison. The presence of a peptide inhibitor prolonged aPTT in a concentration 
dependent manner (Figure 3a), whereas PT remained almost unaffected up to a concentration of 40 µM 
for all peptides tested (Figure 3b). The optimized peptides 61 and 73 inhibited the intrinsic coagulation 
pathway more efficiently than peptide 1. The potency of an intrinsic coagulation inhibitor can be 
expressed as the concentration required to double aPTT (EC2X). Peptides 61 and 73 showed EC2Xs of 1.6 
µM and 2.0 µM, respectively, while peptide 1 had an EC2X of 2.9 µM. 
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Conclusions 
The binding affinity and proteolytic stability of a bicyclic peptide inhibitor of FXIIa were improved 
substantially by synthesizing and screening a library of around 70 variants of an existing peptide 
macrocycle. These variants were created by substituting structurally similar natural and unnatural amino 
acid analogues for various macrocycle residues. It was discovered that the inhibitory activity of the 
bicyclic peptide could be most improved with conservative mutations, such as replacing the atoms in the 
amino acid side chain with halogens or heteroatoms, which resulted in only small structural changes. The 
best affinity improvement, on the order of 10-fold, was achieved by replacing a hydrogen with a fluorine 
atom in para position of a phenylalanine side chain. The blood plasma half-life of the bicyclic peptide was 
improved around 5-fold by replacing the N-terminal arginine with an unnatural arginine analogue.  
 
This work is the first study in which the activity and stability of a phage-selected bicyclic peptide was 
improved by systematically synthesizing and testing a large number of peptide macrocycle variants 
containing unnatural amino acids. The result shows that synthesizing several dozen bicyclic peptide 
variants is sufficient to identify a handful of substitutions that significantly improve the affinity or 
stability. Given that small structural changes most improved the inhibitory activity, it is recommended that 
future optimization of phage-selected bicyclic peptides should be performed by synthesizing variants with 
structurally conservative mutations. 
 
The inhibition constants of the developed bicyclic peptides are several orders of magnitude better than any 
small molecule FXIIa inhibitor reported thus far. The FXIIa inhibitors effectively prolong aPTT while 
leaving PT unchanged. With their favorable binding properties and high stability, the peptide macrocycles 
will be valuable tools to study the biology of FXII and could be exploited as lead structures for the 
development of a therapeutic agent. 
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Experimental Section 
Bicyclic peptide synthesis: 
Peptides were synthesized in house by standard solid-phase peptide synthesis using Fmoc-protected amino 
acids and Rink Amide AM resin on a 0.03 mmol scale. Amino acids were coupled twice at 4-fold molar 
excess using HBTU (4 eq) and HOBt (4 eq) as coupling reagents and DIPEA (6 eq). Coupling of 
unnatural amino acids was performed manually by adding 2 eq of Fmoc-protected amino acid, 2 eq of 
HATU and 4 eq of DIPEA. All peptides synthesized have a free N-terminus and an amidated C-terminus. 
Peptides were cleaved from the resin under reducing conditions (90% TFA, 2.5% H2O, 2,5% thioanisol, 
2,5% phenol, 2.5% 1.2-ethanedithiol). Crude peptide at a concentration of 1 mM was reacted with 1.5 mM 
1,3,5-triacryloyl-1,3,5-triazinane (TATA) in 70% aqueous buffer (50 mM NH4HCO3, pH 8.0) and 30% 
acetonitrile for 1 hour at 30 °C followed by lyophilization. The cyclized peptides were dissolved in 1 ml 
MeCN and 9 ml H2O (containing 0.1% TFA), purified by reversed-phase chromatography on a preparative 
C18 column (Vydac C18 TP1022, 250 x 22 mm, 10 µm) using a linear gradient of solvent B (MeCN, 
0.1% v/v TFA) over solvent A (H2O, 0.1 % v/v TFA) (gradient: 15-28% MeCN in 19 min, flow rate 20 ml 
min
-1
). Pure bicyclic peptides were lyophilized and dissolved in water. The purity of all peptides was 
assessed by analytical HPLC (UV detection at 220 nm) using a C18 column (Agilent Zorbax 300SB, 4.6 
mm x 250 mm, 5 µm, flow: 1 ml min
-1
, gradient: 0-50% solvent B over solvent A in 15 min) and accepted 
if > 95% calculated by integration of the area under the curve. The correct mass of all peptides was 
verified by ESI-MS using a Shimadzu LCMS-2020 with a detector voltage of 1.05 kV. The analytical data 
of all bicyclic peptides is shown in Figure S1 and S2 and Table S1. 
 
Concentration determination of peptide stock solutions 
The concentration of peptide was determined by absorption spectrometry at 280 nm or by weighing the 
lyophilized peptide before dissolving in water, or both. For determining the concentration of peptides by 
absorption spectrometry, theoretical extinction coefficients (ε280) were calculated based on the presence 
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of tryptophan (ε = 5500 M
-1
cm
-1
) and tyrosine (ε = 1490 M
-1
cm
-1
). For determining the concentration of 
peptides by weighing, it was assumed that one trifluoroacetic acid molecule is bound per positive charge 
of the peptide. The concentration of peptides that contain unnatural amino acids absorbing UV light at 280 
nm with unknown ε280, or that lack tryptophan or tyrosine, was determined by weighing. 
 
Protease inhibition assays 
The inhibitory activity of bicyclic peptides was determined by incubation with proteases and 
quantification of the residual activity with a fluorogenic substrate. Residual enzymatic activities were 
measured in buffer containing 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.1% 
w/v BSA, 0.01% v/v Triton-X100, and 1% v/v DMSO in a volume of 150 µL. In a first series of 
experiments, 2.5 nM of enzyme (human β-FXIIa, HFXIIAB; Molecular Innovations) and 50 µM of the 
fluorogenic substrate Z-Gly-Gly-Arg-AMC were used. For measuring the activity of peptides with single-
digit nanomolar or subnanomolar affinity, enzyme was used at a concentration of 0.5 nM in combination 
with the more sensitive substrate Boc-Gln-Gly-Arg-AMC (50 µM). Dilutions of peptides ranging from 
0.01 nM to 4 µM were prepared depending on the binding affinity. Peptides were incubated together with 
the enzyme for 10 min before triggering the reaction by addition of substrate. Fluorescence intensity was 
measured with an Infinite M200Pro fluorescence plate reader (excitation at 368 nm, emission at 467 nm; 
Tecan) for a period of 30 min with a read every minute. The reactions were performed at 25 °C. Sigmoidal 
curves were fitted to the data using the following dose response equation wherein x = peptide 
concentration, y = % protease activity, p = Hill slope. IC50 values were derived from the fitted curve. 
 
 =
100
1 + 10(	 
)
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The bicyclic peptides inhibit most likely, as the parent peptide 1, FXII in a competitive manner. The 
inhibitory constants (Ki) were thus calculated according to the equation of Cheng and Prusoff Ki = 
IC50/(1+([S]0/Km) wherein IC50 is the functional strength of the inhibitor, [S]0 is the total substrate 
concentration, and KM is the Michaelis-Menten constant. KM for the two substrates Z-Gly-Gly-Arg-AMC 
and Boc-Gln-Gly-Arg-AMC were determined to be 180 ± 30 and 260 ± 40 µM, respectively (mean ± SD, 
n = 3-4). 
 
For testing the specificity of the bicyclic peptides, the following final concentrations of human serine 
proteases were used: tPA (Molecular Innovations) 7.5 nM, uPA (Molecular Innovations) 1.5 nM, factor 
XIa (Innovative Research) 6 nM, plasma kallikrein (Innovative Research) 0.25 nM, thrombin (Molecular 
Innovations) 1 nM, plasmin (Molecular Innovations) 2.5 nM, trypsin (Molecular Innovations) 0.05 nM, 
factor VIIa (Haematologic Technologies Inc.) 50 nM and factor Xa (Haematologic Technologies Inc.) 6 
nM. Dilutions of peptide were prepared ranging from 0.04 to 40 µM. The following fluorogenic substrates 
were used at a final concentration of 50 µM: Z-Phe-Arg-AMC (Bachem) for plasma kallikrein, Boc-Phe-
Ser-Arg-AMC (Bachem) for factor XIa, Z-Gly-Gly-Arg-AMC (Bachem) for tPA, uPA, thrombin, and 
trypsin, H-D-Val-Leu-Lys-AMC (Bachem) for plasmin, and D-Phe-Pro-Arg-ANSNH-C4H9 
(Haematologic Technologies Inc.) for FVIIa and FXa. The residual activity of FXIIa (raw data) for the 
most important bicyclic peptides 1, 61 and 73 are shown in Figure S2. 
 
Structural model and structure analysis 
A structural model of the peptide 61-FXIIa complex was obtained by modifying a model of bicyclic 
peptide 1 bound to FXIIa that was previously developed by homology modeling and molecular dynamics 
simulation as described in Baeriswyl, V. et al.
17
 The hydrogen atom in the para position of Phe3 was 
substituted with fluorine using the ‘Build’ function of Pymol. The resulting model for peptide 61 bound to 
FXIIa is provided in the Supporting Information (PDB file FXIIa-61_model). 
Page 15 of 34
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 16 
 
 
Plasma stability assays 
Peptide (2 µl of 2 mM in H2O) was added to 398 µl human plasma (Innovative Research) to obtain a final 
peptide concentration of 10 µM. The mixture was incubated in a water bath at 37 °C. At different time 
points (0, 0.5, 1 , 2 , 4 , 8 , 12, 24 and 48 hr), samples of 30 µl were removed, diluted to 200 µl with 
aqueous buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2) and incubated for 
20 min at 65 °C to inactivate plasma proteases. Control experiments showed that the bicyclic peptide 
remains functional during the protease-inactivation step. The peptide/plasma samples were stored at -20 
°C until the residual inhibitory activity of the peptides was measured in a FXIIa inhibition assay. For the 
activity assay, the peptide/plasma samples were centrifuged for 5 min at 16,000 g and the supernatant was 
collected. Two-fold dilutions of the peptide/plasma samples were prepared (peptide concentration ranges 
from 0.5 nM to 0.5 µM) and the residual activity of 0.5 nM FXIIa with 50 µM Boc-Gln-Gly-Arg-AMC 
substrate was measured. IC50 values were derived from the fitted curve using the equation indicated above. 
Residual inhibition in % was calculated using the equation IC50,0h/IC50,xh*100 wherein IC50,0h  is the 
functional strength of the inhibitor at time point 0 and IC50,xh the functional strength of inhibitor after one 
of the different plasma incubation periods mentioned above. 
 
aPTT and PT coagulant activity measurements 
Coagulation times (aPTT and PT) were determined in human plasma using a STAGO STart4 Coagulation 
analyzer (Diagnostica). Human single donor plasma was used (Innovative Research). For the extrinsic 
coagulation, 50 µl of plasma was placed in the incubating chamber of the instrument for 2 min at 37 °C. 
After incubation, 100 µl of Innovin (recombinant human tissue factor, synthetic phospholipids, and 
calcium in stabilized HEPES buffer system; Dade Behring/Siemens) was added using the pipette 
connected to the instrument. Upon addition of this reagent the electromagnetically induced movement of a 
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steel ball in the plasma was monitored. The time until the ball stops moving was recorded as coagulation 
time. For the intrinsic coagulation, 100 µl of plasma was incubated with 100 µl of Pathromtin* SL (silicon 
dioxide particles, plant phospholipids in HEPES buffer system, Siemens) for 2 min at 37 °C. 
Subsequently, the coagulation was triggered by addition of 100 µl CaCl2 solution (25 mM, Siemens). 
Statistical analysis was performed using the Student’s t-test showing two level of significance (*: p < 0.05 
and **: p < 0.01). 
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Supporting Information 
The Supporting Information is available free of charge on the ACS Publications website at DOI: xyz. 
Analytical data of bicyclic peptides (HPLC chromatograms, MS spectra) 
Raw data of FXII inhibition assay 
Mass table of bicyclic peptides 
Structure model for bicyclic peptide 61 bound to FXIIa (PDB file) 
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Tables 
peptide position substitution Ki (nM) 
2 - - 10.2 ± 0.5 
3 Phe3 Trp 12 ± 2 
4  Tyr 32.2 ± 1.6 
5  Leu 28 ± 5 
6  Pro 36.9 ± 1.2 
7  Ala 132 ± 19 
8  Val 160 ± 20 
9  Ile 310 ± 15 
10 Arg4 Lys 111 ± 8 
11 Leu5 Val 570 ± 60 
12  Ile 890 ± 190 
13  Met > 3000 
14  Ala > 3000 
15 Pro6 Ala 19.6 ± 0.4 
16  Ser 29.4 ± 1.2 
17  Val 47 ± 3 
18  Leu 13.0 ± 1.3 
19  Asn 104 ± 4 
20  Asp 120 ± 30 
21 Gln9 Asp 550 ± 30 
22  Asn 1000 ± 70 
23  Glu > 3000 
24  His > 3000 
25 Leu10 Val 326 ± 12 
26  Ile 78 ± 3 
27  Met 143 ± 5 
28  Ala 1040 ± 90 
 
Table 1. Natural amino acid substitutions in bicyclic peptide 2. Standard deviations of at least three 
measurements are indicated. 
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peptide position substitution Ki (nM) 
29 Phe3 
 
290 ± 4 
30  
 
366 ± 5 
31  
 
> 1000 
32  
 
> 1000 
33 
 
 
6.0 ± 0.6 
34 
 
 
10 ± 2 
35 
 
 
6.8 ± 1.8 
36  
 
94 ± 10 
37  
 
114 ± 10 
38 Arg4  51 ± 18 
39  
 
71 ± 18 
40  
 
156 ± 16 
41  
 
380 ± 40 
42 Leu5  220 ± 80 
43   2700 ± 900 
44  
 
> 3000 
45   > 3000 
46 Leu10 
 
72 ± 5 
47  
 
29.4 ± 1.2 
48  
 
17.7 ± 0.4 
49  
 
30.6 ± 1.2 
50  
 
38 ± 2 
 
Table 2. Unnatural amino acid substitutions in bicyclic peptide 2. Standard deviations of at least three 
measurements are indicated. 
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peptide position substitution Ki (nM) 
51 Phe3 
 
40 ± 2 
52  
 
3.7 ± 0.2 
53  
 
39 ± 6 
54  
 
3.0 ± 0.1 
55  
 
57 ± 7 
56  
 
26.8 ± 0.5 
57  
 
4.5 ± 0.4 
58  
 
0.89 ± 0.15 
59  
 
92 ± 13 
60  
 
1.64 ± 0.19 
 
Table 3. Substitutions of Phe3 in bicyclic peptide 2. Standard deviations of at least three measurements 
are indicated. 
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peptide sequence Ki (nM) 
61 RCF
4-F
RLPCRQLRCR 0.84 ± 0.03 
62 CFRLPCRQLRCR 330 ± 30 
63 RCFRLPCRQLRC 9.3 ± 0.6 
 
Table 4. Removal of the C-terminal tryptophan from bicyclic peptide 58 yielded the bicyclic peptide 61. 
Removal of the N- or C-terminal arginine from bicyclic peptide 1 yielded the bicyclic peptides 62 and 63, 
respectively. Standard deviations of at least three measurements are indicated. 
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peptide position substitution Ki (nM) t1/2 (hrs) 
64 Arg1 Ile 83 ± 3  
65  Val 99 ± 17  
66  Ala 59.2 ± 1.5  
67  Lys 9.0 ± 0.9  
68  D-Arg 34.4 ± 0.7  
69   6.5 ± 0.3 2.0 ± 0.7 
70  
 
8.8 ± 1.4 5 ± 3 
71  
 
14 ± 2 22 ± 3 
72  
 
15 ± 3 13 ± 2 
73 
Arg1 
 
Phe3 
 
4-F-Phe 
1.63 ± 0.18 16 ± 4 
 
Table 5. Substitution of Arg1 in bicyclic peptide 1. The stability in human citrated plasma is indicated as 
half-life, t1/2. Standard deviations of at least three measurements are indicated. 
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Figures 
 
 
 
Figure 1. (a) Schematic representation of bicyclic peptide 1. (b) Structural model for the three key amino 
acids 4-fluoro-phenylalanine (4-F-Phe3), Arg4 and Leu5 of bicyclic peptide 61 bound to FXIIa. Amino 
acids of two surface-exposed loops of FXIIa, surrounding 4-fluoro-phenylalanine are shown in yellow. 
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Figure 2. (a) Stability of bicyclic peptides in human plasma. The apparent IC50 was determined after 
incubating the peptides in human plasma at 37 °C for the indicated time periods. Average values of three 
measurements are indicated. (b) Specificity of bicyclic peptide 73. Average values of at least three 
measurements. Standard deviations are indicated. 
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Figure 3. Coagulation parameters aPTT (a) and PT (b) for bicyclic peptides 1, 61 and 73. Standard 
deviations of aPTT, PT are calculated based on three measurements (*: p < 0.05; **: p < 0.01).  
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